Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Picard Medical, Inc. ( (PMI) ) has shared an update.
On March 13, 2026, Picard Medical announced that its SynCardia Total Artificial Heart will be featured on BTV – Business Television, with a segment airing on FOX Business News on March 14, 2026 at 5:00 p.m. Eastern Time. The broadcast aims to showcase how the device replaces the pumping function of a failing heart for patients awaiting transplantation and underscores SynCardia’s role as a leader in total artificial heart technology.
The segment will also spotlight Picard Medical’s development of a next‑generation, fully implantable artificial heart platform intended to eliminate external pneumatic drivers and improve patient mobility and quality of life. By appearing on an investment‑focused program with broad distribution to retail and institutional investors, the company is seeking to raise awareness of advanced heart failure therapies and increase visibility of its current and future artificial heart solutions among key stakeholders.
The most recent analyst rating on (PMI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.
Spark’s Take on PMI Stock
According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.
The score is held down mainly by very weak fundamentals (large ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates and financing improve near-term runway and visibility, but do not yet offset the current profitability and cash-flow risks.
To see Spark’s full report on PMI stock, click here.
More about Picard Medical, Inc.
Picard Medical, Inc., listed on NYSE American as PMI, is the parent of Tucson‑based SynCardia Systems, which develops, manufactures, and commercializes the SynCardia Total Artificial Heart for patients with end‑stage heart failure. The SynCardia device, approved by both the U.S. FDA and Health Canada and used in over 2,100 implants across 27 countries, is currently the only commercially available total artificial heart in the United States and Canada.
SynCardia’s Total Artificial Heart is an implantable system that completely replaces both ventricles and all four heart valves, assuming the full circulatory function of a failing or failed human heart. Positioned as the most widely used and extensively studied artificial heart technology globally, the platform targets patients with severe biventricular heart failure who face imminent risk of death without mechanical circulatory support.
Average Trading Volume: 812,532
Technical Sentiment Signal: Strong Sell
Learn more about PMI stock on TipRanks’ Stock Analysis page.